From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloid precursor protein(APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease .
Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC50 = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
β-Amyloid/A4 Protein Precusor (319-335) (APP (319-335)) is a peptide fragment of β-Amyloid/A4 protein precursor (APP). β-Amyloid/A4 Protein Precusor (319-335) can recognize the heparinase-insensitive site that contains the neuritotropic activity of APP .
Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine tartrate reduces β-amyloid precursor protein(APP) and β-amyloid peptide (Aβ) formation. Phenserine tartrate improves cognitive performance and attenuates the progression of Alzheimer's disease .
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .
α-Secretase Substrate II, Fluorogenic is an internally quenched fluorogenic peptide substrate for α-Secretase that contains the α-secretase cleavage site of β-Amyloid precursor protein (APP) .Ex/Em = 340/490 nm
cis-Miyabenol C is an isomer of the resveratrol trimer Miyabenol C, which can be isolated from grape herbs. Miyabenol C is an inhibitor of β-amyloid (Aβ) and amyloid β precursor protein(APP) in Alzheimer's disease model mice, and inhibit β-secretase activity without changing the protein level of β-secretase BACE1 .
gamma-secretase modulator 6 (Example 50) is a gamma-secretase modulator. gamma-secretase modulator 6 inhibits Aβ42 secretion in HEK cell line stably expressing APP (Aβ amyloid precursor protein) (pIC50: 8.1). gamma-secretase modulator 6 can be used for research of Alzheimer's disease .
Cholesterol (Excipient) (Standard) is the analytical standard of Cholesterol (Excipient) (HY-N0322B). This product is intended for research and analytical applications. Cholesterol Excipient is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity. Cholesterol Excipient is a drug delivery carrier based on the lipid environment of the cell membrane. Due to its amphiphilicity, good biocompatibility and biodegradability, it can be used as an excipient in drug preparations. Cholesterol Excipient can self-assemble into delivery systems such as micelles, nanoparticles, and liposomes, and achieve controlled drug release by regulating membrane fluidity or responding to the microenvironment. It has the characteristics of high drug loading efficiency and good biocompatibility. Cholesterol Excipient is mainly used for research in the fields of targeted delivery of anticancer, antibacterial, antiviral drugs and treatment of skin diseases.
Cholesterol itself is also an endogenous regulator involved in the cleavage of amyloid precursor protein (APP) mediated by β-secretase and intestinal absorption, as well as an endogenous estrogen-related receptor α (ERRα) agonist. Cholesterol affects the subcellular localization of APP processing enzymes by regulating the cell membrane lipid environment, which can promote the production of β-amyloidprotein and its adsorption and removal by probiotics. It is used to study the pathogenesis of Alzheimer's disease (AD) and the cholesterol-lowering function of probiotics[1][2][3][4][5].
AZD3839 is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 can be used in the field of Alzheimer's disease research .
Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity.
In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloidprotein and enhances the secretion of Aβ1-40 in HEK cells transfected with APP .
In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol . Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation . Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .
β-Amyloid/A4 Protein Precusor (319-335) (APP (319-335)) is a peptide fragment of β-Amyloid/A4 protein precursor (APP). β-Amyloid/A4 Protein Precusor (319-335) can recognize the heparinase-insensitive site that contains the neuritotropic activity of APP .
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .
α-Secretase Substrate II, Fluorogenic is an internally quenched fluorogenic peptide substrate for α-Secretase that contains the α-secretase cleavage site of β-Amyloid precursor protein (APP) .Ex/Em = 340/490 nm
[Asn23] β-Amyloid (1-40), Iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)
[Asn23]-beta-Amyloid (1-42), iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)
cis-Miyabenol C is an isomer of the resveratrol trimer Miyabenol C, which can be isolated from grape herbs. Miyabenol C is an inhibitor of β-amyloid (Aβ) and amyloid β precursor protein(APP) in Alzheimer's disease model mice, and inhibit β-secretase activity without changing the protein level of β-secretase BACE1 .
beta Amyloid 1-42 Antibody (YA3555) is an unconjugated, approximately 4 kDa, rabbit-derived, anti-beta Amyloid 1-42 monoclonal antibody.beta Amyloid 1-42 Antibody (YA3555) can be used for: WB, IHC-P, IF-Tissue expriments in human, mouse background without labeling.
beta-amyloid(1-42); A4; AAA; ABETA; ABPP; AD1; Alzheimers Disease amyloidprotein; amyloid B; amyloid beta A4 protein Precursor; amyloid beta; amyloid of Aging and Alzheimer Disease; APP; APPI; B amyloid; beta APP; Cerebral Vascular amyloid Peptide; CTFgamma; CVAP; PN II; PN2; PreA4; Protease nexin II; A beta; amyloid 1-42.
WB, IHC-P, IHC-F, IF-Tissue
Human
beta-Amyloid(1-42) Antibody (YA6439) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid (1-42). It can be applicated for WB, IHC-P, IHC-F, IF-Tissue assays, in the background of human.
beta Amyloid 1-40 Antibody (YA3554) is an unconjugated, approximately 4 kDa, rabbit-derived, anti-beta Amyloid 1-40 monoclonal antibody.beta Amyloid 1-40 Antibody (YA3554) can be used for: WB, IHC-P, IF-Tissue expriments in human, mouse background without labeling. beta Amyloid 1-40 Antibody (YA3554) recognizes Aβ-40 peptide. This antibody does not cross-react with other β-amyloid peptides.
beta Amyloid Antibody (YA3556) is an unconjugated, approximately 4 kDa, rabbit-derived, anti-beta Amyloid monoclonal antibody.beta Amyloid Antibody (YA3555) can be used for: WB, IHC-P, IF-Tissue, Dot Blot expriments in human, mouse background without labeling.
Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity.
In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloidprotein and enhances the secretion of Aβ1-40 in HEK cells transfected with APP .
In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol . Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation . Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .
Inquiry Online
Your information is safe with us. * Required Fields.
